Monday, 16 Sep 2019

You are here

Gout is Undermanaged

Gout should be one of the easiest and best managed of rheumatic disorders.  However, numerous deficits exist with regard to the treatment and long-term care of gout.

Swedish investigators have assessed the likelihood of gout patients that would receive and persist with urate lowering therapy.

Using a population-based cohort of 7709 incident gout patients from western Sweden they found that within the first year of their gout diagnosis, 32% received ULT.  Higher rates of ULT were seen in males, and those patients with diabetes, cardiovascular and renal disease.

However, a majority (75%) did not persist with ULT treatment within the first 2 years. Age <50 years, lack of comorbidities, and “normal kidney function” or “end-stage kidney failure” were associated with non-persistence with ULT.

Only a minority of patients received ULT and a majority of these did not persist with treatment over the next 2 years.  Persistent therapy was more likely in older patients and those with renal impairment and comorbidities.

Although there was no control group or "gold standard" for persistence, it seems obvious that those who need ULT, should remain on ULT.

Gout continues to be undermanaged by those who believe they can manage gout. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.